» Articles » PMID: 38057654

Antifungal Properties of Cathelicidin LL-37: Current Knowledge and Future Research Directions

Overview
Publisher Springer
Date 2023 Dec 6
PMID 38057654
Authors
Affiliations
Soon will be listed here.
Abstract

The threat of fungal diseases is substantially underestimated worldwide, but they have serious consequences for humans, animals, and plants. Given the limited number of existing antifungal drugs together with the emergence of drug-resistant strains, many researchers have actively sought alternatives or adjuvants to antimycotics. The best way to tackle these issues is to unearth potential antifungal agents with new modes of action. Antimicrobial peptides are being hailed as a promising source of novel antimicrobials since they exhibit rapid and broad-spectrum microbicidal activities with a reduced likelihood of developing drug resistance. Recent years have witnessed an explosion in knowledge on microbicidal activity of LL-37, the sole human cathelicidin. Herein, we provide a summary of the current understanding about antifungal properties of LL-37, with particular emphasis on its molecular mechanisms. We further illustrate fruitful areas for future research. LL-37 is able to inhibit the growth of clinically and agronomically relevant fungi including Aspergillus, Candida, Colletotrichum, Fusarium, Malassezia, Pythium, and Trichophyton. Destruction of the cell wall integrity, membrane permeabilization, induction of oxidative stress, disruption of endoplasmic reticulum homeostasis, formation of autophagy-like structures, alterations in expression of numerous fungal genes, and inhibition of cell cycle progression are the key mechanisms underlying antifungal effects of LL-37. Burgeoning evidence also suggests that LL-37 may act as a potential anti-virulence peptide. It is hoped that this review will not only motivate researchers to conduct more detailed studies in this field, but also inspire further innovations in the design of LL-37-based drugs for the treatment of fungal infections.

Citing Articles

Human antimicrobial/host defense peptide LL-37 may prevent the spread of a local infection through multiple mechanisms: an update.

Svensson D, Nilsson B Inflamm Res. 2025; 74(1):36.

PMID: 40063262 PMC: 11893641. DOI: 10.1007/s00011-025-02005-8.


Therapeutic potential of mesenchymal stem cells for fungal infections: mechanisms, applications, and challenges.

Gao Y, Ji Z, Zhao J, Gu J Front Microbiol. 2025; 16:1554917.

PMID: 39949625 PMC: 11821621. DOI: 10.3389/fmicb.2025.1554917.


Effects of the Tobacco Defensin NaD1 Against Susceptible and Resistant Strains of .

Shevchenko O, Voropaev A, Bogdanov I, Ovchinnikova T, Finkina E Pathogens. 2025; 13(12.

PMID: 39770352 PMC: 11678012. DOI: 10.3390/pathogens13121092.


Antifungal peptides from living organisms.

Gong Y, Xue Q, Li J, Zhang S Front Microbiol. 2025; 15:1511461.

PMID: 39741586 PMC: 11685209. DOI: 10.3389/fmicb.2024.1511461.


Biomimetic Antifungal Materials: Countering the Challenge of Multidrug-Resistant Fungi.

Khalifa H, Oreiby A, Abdelhamid M, Ki M, Pack S Biomimetics (Basel). 2024; 9(7).

PMID: 39056866 PMC: 11274442. DOI: 10.3390/biomimetics9070425.


References
1.
Adedara I, Owumi S . Neurobehavioral and biochemical responses to artemisinin-based drug and aflatoxin B co-exposure in rats. Mycotoxin Res. 2023; 39(1):67-80. DOI: 10.1007/s12550-023-00474-6. View

2.
Agerberth B, Buentke E, Bergman P, Eshaghi H, Gabrielsson S, Gudmundsson G . Malassezia sympodialis differently affects the expression of LL-37 in dendritic cells from atopic eczema patients and healthy individuals. Allergy. 2006; 61(4):422-30. DOI: 10.1111/j.1398-9995.2005.00952.x. View

3.
Aghazadeh H, Memariani H, Ranjbar R, Pooshang Bagheri K . The activity and action mechanism of novel short selective LL-37-derived anticancer peptides against clinical isolates of Escherichia coli. Chem Biol Drug Des. 2018; 93(1):75-83. DOI: 10.1111/cbdd.13381. View

4.
Alford M, Baquir B, Santana F, Haney E, Hancock R . Cathelicidin Host Defense Peptides and Inflammatory Signaling: Striking a Balance. Front Microbiol. 2020; 11:1902. PMC: 7481365. DOI: 10.3389/fmicb.2020.01902. View

5.
Alves V, Araujo G, Frases S . Off-label treatments as potential accelerators in the search for the ideal antifungal treatment of cryptococcosis. Future Microbiol. 2023; 18:127-135. DOI: 10.2217/fmb-2022-0122. View